ENGLEWOOD, Colo., May 18, 2020 /PRNewswire/ -- Zynex, Inc.
(NASDAQ: ZYXI), an innovative medical technology company
specializing in the manufacture and sale of non-invasive medical
devices for pain management, stroke rehabilitation, cardiac
monitoring and neurological diagnostics, today announced it has
introduced a full catalog of physical therapy products for
distribution through its US sales force.
Thomas Sandgaard, CEO said: "I am
pleased to announce our catalog with over 3,300 products for our
sales force to promote in the clinics across the country and allow
us to continue to build strong relationships with prescribers and
clinics we already serve.
The catalog is full of well-known brand names from manufacturers
such as CanDo, Mettler, Richmar, Chattanooga, GameReady, Theratherm,
Manosplint, Orfit, Baseline, TOGU, and Armedica to name a few.
These products will be sold directly to clinics and therefore not
require any insurance billing.
In the first quarter, we continued to focus on the execution of
our growth strategy and the related growth of our sales force by
adding 150 sales reps so far in 2020. Our sales force is now up to
a total of 285 that will begin promoting all these products
starting this week.
We continue to advocate for pain patients, and for physicians to
prescribe our NexWave technology as the first line of defense in
treating chronic and acute pain without side effects. We are
dedicated to promoting our technology in an effort to remove
patient addiction and other side effects from prescription
About Zynex, Inc.
Zynex, founded in
1996, markets and sells its own design of electrotherapy medical
devices used for pain management and rehabilitation; and the
company's proprietary NeuroMove device designed to help recovery of
stroke and spinal cord injury patients. Zynex also has a blood
volume monitor for use in hospitals and surgery centers. For
additional information, please visit: www.zynex.com.
Safe Harbor Statement
This release contains
forward-looking statements within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, projections,
anticipated events and trends, the economy and other future
conditions. Because forward-looking statements relate to
the future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results and financial
condition may differ materially from those indicated in the
forward-looking statements. Therefore you should not rely on any of
these forward looking statements. The Company makes no
express or implied representation or warranty as to the
completeness of forward looking statements or, in the case of
projections, as to their attainability or the accuracy and
completeness of the assumptions from which they are derived.
Factors that could cause actual results to materially differ from
forward-looking statements include, but are not limited to, the
need to obtain CE marking of new products, the acceptance of new
products as well as existing products by doctors and hospitals,
larger competitors with greater financial resources, the need to
keep pace with technological changes, our dependence on the
reimbursement for our products from health insurance companies, our
dependence on third party manufacturers to produce our goods on
time and to our specifications, implementation of our sales
strategy including a strong direct sales force, the impact of
COVID-19 on the global economy and other risks described in our
filings with the Securities and Exchange Commission including our
Annual Report on Form 10-K for the year ended December 31,
2019 as well as our quarterly reports on Form 10-Q and current
reports on Form 8-K.
Any forward-looking statement made by us in this release is
based only on information currently available to us and speaks only
as of the date on which it is made. We undertake no obligation to
publicly update any forward-looking statement, whether written or
oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.
Contact: Zynex, Inc. (303) 703-4906
Investor Relations Contact:
Amato And Partners,
Investor Relations Counsel
View original content to download